05Sep 2021
Difamilast ointment, a selective phosphodiesterase 4 inhibitor, in paediatric patients with atopic dermatitis: A phase 3 randomised double‐blind, vehicle‐controlled trial

Difamilast ointment, a selective phosphodiesterase 4 inhibitor, in paediatric patients with atopic dermatitis: A phase 3 randomised double‐blind, vehicle‐controlled trial

In atopic dermatitis (AD), phosphodiesterase 4 (PDE4) inhibition reduces proinflammatory mediators and cytokines. Difamilast is a new selective PDE4 inhibitor. We aimed to demonstrate the superiority of topical difamilast to vehicle in Japanese paediatric patients with AD. EASI score in difamilast 0·3% and 1% was significantly reduced compared with that of vehicle at week 1, and the significant difference between both difamilast and vehicle groups was maintained from week 1 through week 4. The success rates in IGA score at week 4 were 44·6%, 47·1%, and 18·1% in the difamilast 0·3%, difamilast 1%, and vehicle groups, respectively. Difamilast 0·3% and 1% ointments are superior to vehicle and well tolerated in Japanese paediatric patients with AD.

  • #dermatology

Like

Save

Share